Anticoagulation in clinical practice -2nd Part: the use of heparins

Authors

  • Ana Teresa Timóteo Interna do Internato Complementar de Cardiologia, Hospital de Santa Cruz, Carnaxide
  • Maria João Pais Chefe de Serviço de Medicina Interna, Hospital de Santa Cruz, Carnaxide

Keywords:

unfractionated heparin, low-mo­lecular weight heparin, thrombocytopenia, anti­ Xa activity

Abstract

The authors review, in this, the second part of the theme "anticoagulation in clinical prac­tice", the use of heparins in clinical practice. First, the use of unfractionated heparin, is discussed its indicated uses in inpatients, with often consequent long in-patient admission ti­mes, as well as the disadvantages of its use on the outpatient basis e.g. difficult use at home and complex monitorisation. Secondly, the authors' present low molecular weight hepa­rins, which combine easy administration with easy monitorisation, making their total cost lower than that of unfractionated heparin. Caution must be exercised in their implemen­tation, as each low molecular weight heparin has an individual profile that must be asses­sed in each clinical situation. To date, all studies point to a beneficial effect with the use of the various unfractionated heparins in their different clinical settings. lt seems probable that new indications will appear.

Downloads

Download data is not yet available.

References

Choay J. Structure and activity of low molecular weight heparins. ln: Christian Doutremepuich. ed. Low molecu­lar weight heparins in clinical practice, Nova Iorque, Mar­ cel Dekker, inc 1992: 1-6.

Hoppenstead DA, Jeske W, Ahsan A, Walenga JM, Fareed J. Biochemical and pharmacological profile of defined molecular weight fractions of heparin. Seminars in throm­bosis and hemostasis 1993; 19( 1): 12-19.

Fareed J. Hoppensteadt DA, Walenga JM. Current pres­ pectives on low molecular weight heparins. Seminars in thrombosis and hemostasis 1993; 190 ): 1-11.

Handin RJ. Anticoagulant. fibrinolytic and antiplatelet therapy. ln: Isselbacher KJ, 8raunwakl E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principies of Internal Medicine, Nova Iorque. McGraw-Hill. inc 1994: 1810-1813.

Hirsh J. Heparin. N Engl J.Med 1991; 324: 1565-1574.

Morais S, Campos M, Justiça B. Prevenção e tratamento da trombose. Porto: Hospital Geral de Santo António. 1995: 24-25.

Ginsberg JS. Management of venous thromboemholism. N Engl J Med 1996; 335: 1816-1828.

Bergqvist D. Principal view on dose adjustment of low molecular weight heparins. Seminars in thrombosis and hemostasis 1993: 19( 1): 107-110.

Warkentin TE, Levine MN, Hirh J et al. Heparin-induced thrombocytopenia in patients treted with low molecular weight heparins or unfractionated heparins. N Eng! J Med 1995; 332: 1330-1335.

Aster RH. Heparin-induced thrombocytopenia and throm­bosis. N Eng! J Med 1995; 332: 1374-1376.

Schmitt Y, Schneider H. Low molecular weight heparin: influence on blood lipids in patients on chronic haemo­dialisis. Nephrol Dial Transplant 1993; 8: 438-442.

Mardiguian J. Methods of preparation of low molecular weight heparins. In: Christian Doutremepuich ed. Low molecular weight heparins in clinical practice. Nova Ior­que, Marcel Dekker, inc 1992: 7-12.

Ofosu FA. Mechanisms of actions of low molecular wei­ght heparin fractions. In: Christian Doutremepuich, ed. Low molecular weight heparins in clinical practice. Nova Iorque, Marcel Dikker. inc 1992: 13-21.

Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins. Seminars in thrombosis and hemostasis 1993; 19 ( 1): 97-100.

Schafer AI. Low molecular weight heparins-an opportu­nity for home treatment of venous thrombosis. N Engl J Med 1996; 334 724-725.

Levine M, Gent M, Hirsh J et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospi­tal for deep-vein thrombosis. N Engl J Med 1996, 334: 677-681.

Vairel EG: Hepanns and fibrinolysis. In: Christian Doutre­ mepuich, ed. Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 51-61.

Fareed J, Jeske W, Eschenfelder V et al. Preclinical studies on a low molecular weight heparin. Thrombosis research, 1996; 81 (Supl )1: S1-S27.

Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698

Barrowdiffe TW: Standardization of assays of low mo­lecular weight heparins. In: Christian Doutremepuich, ed.Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 155-169.

Walenga JM. Practical issues on the laboratory monito­ring of low molecular weight heparins and related po­lyssaccharides. Seminars in thrombosis and hemostasis 1993: 19 e n 69-72.

Bouthier J, Kher A, Frapaise FX et al. Some commercial low molecular weight heparins. In: Christian Doutreme­puich, ed.Low molecular weight heparins in clinical prac­tice, Nova Iorque, Marcel Dekker, inc 1992: 199-244.

Boisseau MR. Prophylaxis of deep vein thrombosis with low molecular weight heparins. In: Christian Doutreme­puich, ed. Low molecular weight heparins in clinical prac­tice, Nova Iorque, Marcel Dekker, inc 1992: 125-136.

Eriksson BI, Kalebo P, Risberg B. Clinical experience of a low molecular weight heparin (Fragmin) in the pre­ vention of thromboemholism after total hip replacement Seminars in thrombosis and hemostasis 1993; 19 (1 ):122-127.

Bergqvist D. Benoni G, Bjürgell O et al. Low molecular weight heparin (enoxaparin) asptophylaxis against thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.

Geerts WH, Jay RM, Code KI, A comparison of low­ dose heparin with low molecular weight heparin as pro­phylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707.

The Columbus investigators. Low-molecular-weight he­parin in the treatment of patients with venous thrombo­ embolism. N Engl J Med 1997; 337: 657-662

Simonneau G, Sors H, Charbonnier et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.

Janvier G, Winnack S. Treatment of deep vein throm­bosis with low molecular weight heparins. ln: Christian Doutremepuich, ed. Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 109-124.

Koopman MMW, Pramloni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administe­red at home. N Engl J Med 1996; 334: 682-687.

Breddin HK. Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight hepa­rins? Thrombosis Research 1996; 81 (Supl): S47-S51.

Preisack MB, Karsch KR. Low molecular weight hepa­rins in prevention of restenosis after PTCA. Thromhosis Research 1996; 81 (Supl): S53-S59.

Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins, Seminars in thrombosis and hemostasis 1993; 19( 1): 97-100.

Vukusich A, Avalos C, Orellana G, et ai. Anticoagulaci­on en hemodialisis con dosis unica de heparina de bajo peso molecular. Rev Med Chil 1995; 123: 735-741.

Additional Files

Published

1998-12-31

How to Cite

1.
Timóteo AT, Pais MJ. Anticoagulation in clinical practice -2nd Part: the use of heparins. RPMI [Internet]. 1998 Dec. 31 [cited 2024 Nov. 22];5(4):264-70. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/2163

Issue

Section

Review Articles